

بسم الله الرحمن الرحيم





شبكة المعلومات الجامعية التوثيق الالكتروني والميكروفيلم



جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار





بعض الوثائق الأصلية تالفة





بالرسالة صفحات
لم ترد بالأصل





Chemotherapy toxicity profile in adjuvant treated colorectal carcinoma patients in Ain Shams oncology department

Retrospective study
Submitted for Partial Fulfillment of Master Degree in
Clinical Oncology

By

Mohammed Abdallah Fathy
Faculty of Medicine
Ain Shams university
M.B.B.CH

Supervised by

Ass. Prof. Dr. Nagy Samy Gobran
Associate Professor of Clinical Oncology and
Nuclear Medicine
Faculty of Medicine, Ain Shams University

Dr. Mohammed Reda Kelany
Lecturer of Clinical Oncology and Nuclear Medicine
Faculty of Medicine, Ain Shams University

Faculty of Medicine
Ain Shams University
2020

Acknowledgment

First and foremost, thanks to **ALLAH**. The creator of all, for helping me to achieve this work.

I wish to express my deepest gratitude and obligations to **Prof. Dr. Nagy Sami Gobran**

Associate Professor of clinical oncology, Faculty of Medicine, Ain Shams University, for his meticulous supervision for all aspects of this work, valuable advice, and enormous effort and help throughout the work.

I am deeply indebted to **Dr. Mohamed Reda Kelany** Lecturer of Clinical Oncology & Nuclear Medicine Department, Faculty of Medicine, Ain Shams University, for his kind supervision, great help and valuable advice throughout the work.

I would like to express my great thanks to all staff members of Clinical Oncology & Nuclear Medicine Department, Faculty of Medicine, for their kind support and cooperation.

Finally, my sincere appreciation is also extended to my colleagues, patients, and everybody who had shared by any way in the performance of this work

Mohammed Abdallah Fathy

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

سبحانك لا علم لنا
إلا ما علمتنا إنك أنت
العليم العليم

صدق الله العظيم

سورة البقرة الآية: ٣٢

List of Contents

Title	Page No.
List of Tables	i
List of Figures	ii
List of Abbreviations.....	iv
Introduction	1
Aim Of The Study	3
Review of literature	
✎ Chapter 1: Epidemiology.....	4
✎ Chapter 2: Etiology And Risk Factors	10
✎ Chapter 3: Pathology.....	17
✎ Chapter 4: Staging Of CRC.....	28
✎ Chapter 5: Treatment	31
✎ Chapter 6: Chemotherapy Agents' Side Effects	41
Patients And Methods	70
Results.....	73
Discussion	102
Summary And Conclusion	109
References	111
Arabic Summary	-

List of Tables

Table No.	Title	Page No.
Table (1):	Classification Based on Clinical, Morphological, and Molecular Features	24
Table (2):	CRC Molecular Subtype Classification by TCGA (TCGA classification)	25
Table (3):	CRC Molecular Subtype Classification by Gene Expression Profiling (CMS Classification)	27
Table (4):	T.N.M classification of colorectal cancer (AJCC 8th edition).....	28
Table (5):	Anatomic stage/prognostic groups	30
Table (6):	Age rang and percent of sex	73
Table (7):	Dignosis and staging	74
Table (8):	Chemotherapy protocols and number of cycles	78
Table (9):	Oxaliplatin cumulative dose and dose reduction	80
Table (10):	Percentage of Co morbidities	82
Table (11):	Descriptive statistical analysis of all recorded toxicities.....	83
Table (12):	Correlation between age and toxicity	91
Table (13):	Correlation between gender and toxicity	93
Table (14):	Correlation between cumulative dose of oxaliplatin and toxicity	95
Table (15):	Correlation between chemotherapy type and toxicity	99

List of Figures

Fig. No.	Title	Page No.
Figure (1):	Incidence of CRC in males	4
Figure (2):	Incidence of CRC in females	5
Figure (3):	CRC incidence rates by sex and world areas.....	6
Figure (4):	Low rate of CRC in Egypt	7
Figure (5):	Incidence and mortality of CRC in USA.....	9
Figure (6):	Adenoma – carcinoma sequence	18
Figure (7):	The two genetic pathway of colorectal cancer	19
Figure (8):	Kaplan meier estimate of O.S in MOSAIC trial.....	36
Figure (9):	Kaplan meier estimate of DFS in MOSAIC trial.....	37
Figure (10):	Kaplan meier curve of IDEA collaboration phase 3 trial.....	39
Figure (11):	Mechanism of action of 5-flurouracil	64
Figure (12):	Male to female ratio	73
Figure (13):	Percentage of colon and rectal cancer.....	75
Figure (14):	Anatomical location of tumor.....	75
Figure (15):	Percentage of tumor grades	76
Figure (16):	Percentage of T staging	76
Figure (17):	Percentage of N staging	77
Figure (18):	Number of chemotherapy cycles received	79
Figure (19):	Types of chemotherapy protocols received	79
Figure (20):	Oxaliplatin cumulative dose	80
Figure (21):	Percent of patients underwent dose reduction	81
Figure (22):	Percent of patients stopped chemotherapy	81
Figure (23):	Percent of patients have comorbidities	82
Figure (24):	Incidence of neurological toxicity.....	85
Figure (25):	Incidence of anemia.....	85
Figure (26):	Incidence of thrombocytopenia	86
Figure (27):	Incidence of neutropenia	86
Figure (28):	Incidence of dermatological toxicity	87

List of Figures

Fig. No.	Title	Page No.
Figure (29):	Incidence of nausea	87
Figure (30):	Incidence of vomiting	88
Figure (31):	Incidence of diarrhea.....	88
Figure (32):	Incidence of allergy.....	89
Figure (33):	Incidence of hepatic toxicity.....	89
Figure (34):	Incidence of other toxicity	90
Figure (35):	Correlation between age and neurological toxicity	92
Figure (36):	Correlation between age and fatigue.....	92
Figure (37):	Correlation between gender and anemia	94
Figure (38):	Correlation between oxaliplatin cumulative dose and neurological toxicity	97
Figure (39):	Correlation between oxaliplatin cumulative dose and renal toxicity	97
Figure (40):	Correlation between oxaliplatin cumulative dose and thrombocytopenia	98
Figure (41):	Correlation between type of chemotherapy and neurological toxicity	101
Figure (42):	Correlation between type of chemotherapy and dermatological toxicity.....	101

List of Abbreviations

Abb.	Meaning
<i>5 FU</i>	<i>5- fluorouracil</i>
<i>ACCORD</i>	Action Clinique Coordonnées en Cancérologie digestive
<i>ADT</i>	Androgen deprivation therapy
<i>AFAP</i>	Attenuated familial adenomatous polyposis
<i>AJCC</i>	American joint committee of cancer
<i>ASCO</i>	American society of clinical oncology
<i>BAK</i>	Baclophen, Amitriptyline & Ketamine
<i>BPI-SF</i>	Brief pain inventory – short form
<i>BRCA</i>	Breast cancer gene
<i>CALGB</i>	Cancer & leukemia group
<i>CIMP</i>	CpG island methylator phenotype
<i>CIN</i>	Chromosomal instability
<i>CME</i>	Complete mesorectal excision
<i>CMS</i>	Consensus molecular subtype
<i>CNS</i>	Central nervous system
<i>CNV</i>	Copy number variation
<i>CRC</i>	Colorectal cancer
<i>CT</i>	Computed tomography

List of Abbreviations

Abb.	Meaning
<i>CTCAE</i>	<i>Common terminology criteria of adverse events</i>
<i>CTNNB1</i>	Catenin Beta 1
<i>DFS</i>	Disease free survival
<i>DPD</i>	Dihydropyrimidine dehydrogenase
<i>DRE</i>	Digital rectal examination
<i>ECOG</i>	Eastern cooperative oncology group
<i>EGFR</i>	Epidermal growth factor receptor
<i>EORTC</i>	European organization for research & treatment of cancer
<i>FACT</i>	Functional assessment of cancer
<i>FAP</i>	Familial adenomatous polyposis
<i>GI</i>	Gastro intestinal
<i>GOG</i>	Gynecology oncology group
<i>HFS</i>	Hand foot syndrome
<i>HNPCC</i>	Hereditary non polyposis colorectal can
<i>HORG</i>	Hellenic oncology research group
<i>HPV</i>	Human papilloma virus
<i>HRAS</i>	Harvey rat sarcoma oncogene
<i>IENFD</i>	Intra epidermal nerve fiber density

List of Abbreviations

Abb.	Meaning
<i>IMPACT</i>	<i>International multicenter pooled analysis of CRC trial</i>
<i>KRAS</i>	Kirsten rat sarcoma gene
<i>LOH</i>	Loss of heterogeneity
<i>LV</i>	Leucovorin
<i>MAP</i>	MutYh adenomatous polyposis
<i>MAPK</i>	Mitogen activated protein kinase
<i>MASCC</i>	Multinational association of supportive care in cancer
<i>MBC</i>	Metastatic breast cancer
<i>MCRC</i>	Metastatic colorectal cancer
<i>MMR</i>	Mismatch repair
<i>MOSAIC</i>	Multicenter international study of oxaliplatin/5FU-LV in adjuvant treatment of colon cancer
<i>MRC</i>	Medical research council
<i>MRI</i>	Magnetic resonance image
<i>MSH 3</i>	Mut S homologue 3
<i>MSI</i>	Microsatellite instability
<i>MSI-H</i>	Microsatellite instability high
<i>MSS</i>	Microsatellite stable
<i>MUTYH</i>	Mut Y homologue